Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Investor Presentation (December 2018)
21 slides from Botanix Pharmaceuticals's investor presentation, Dec 5, 2018
Slide 1: ASX/Media Release: Updated investor presentation
ASX/Media Release 5 December 2018 For personal use only Updated investor presentation Philadelphia PA and Sydney Australia, 5 December 2018: Medical dermatology company Botanix Pharmaceuticals (“Botanix” or “the Company”) is pleased to release an updated investor presentation, to be presented to inv
Slide 2: Botanix Overview - Canada, December 2018
For personal use only Botanix Overview Canada December 2018 1
Slide 3: Key investment highlights
Key investment highlights Botanix is a global dermatology company delivering synthetic cannabinoids topically for the treatment of skin diseases For personal use only Dermatology Advanced clinical programs targeting multi-billion dollar prescription markets for acne, atopic focused dermatitis and ps
Slide 4: Permetrex skin delivery technology
Permetrex™ skin delivery technology Proprietary Permetrex™ technology delivers high doses of drug into the layers of the skin without use of permeation enhancers, preservatives, or the use of irritating alcohol/petrolatum additives For personal use only Unmodified Drug With Permetrex™ Formulation te
Slide 5: Permetrex technology enables superior delivery of cannabidiol
Permetrex™ technology enables superior delivery of cannabidiol Permetrex™ delivers more much more cannabidiol (CBD) into the target layers of the skin, even though the CBD concentration of the BTX 1503 formulation is only 25% to 50% the concentration of alternative formulations For personal use only
Slide 6: Clinical programs with near term milestones
Clinical programs with near term milestones Phase 2 acne and atopic dermatitis programs supported by exciting development pipeline, with Permetrex™ collaborations to augment revenue and news flow For personal use only Product candidate Indication Pre-clin Ph 1 Ph 1b Ph 2 Next milestones Moderate to
Slide 7: Development Pipeline
Development Pipeline BTX 1503: acne For personal use only BTX 1204: atopic dermatitis BTX 1308: psoriasis BTX 1801: antimicrobial 6 Botanix Overview – December 2018
Slide 8: BTX 1503: acne – mechanism of action for acne
Acne BTX 1503: acne – mechanism of action for acne BTX 1503 is a safe and well tolerated topical treatment that addresses all 3 key pathologies of acne For personal use only CBD addresses multiple pathologies that contribute to CBD has been shown to… acne in a CB1/CB2 independent manner1 Have anti-i
Slide 9: BTX 1503: acne – outperforms leading acne products
Acne BTX 1503: acne – outperforms leading acne products 4 week study data shows a marked reduction in inflammatory lesions, greater than any other FDA approved topical acne product 1 For personal use only Lesion count reduction (%) Comparison with other FDA approved products Product Owner Lesion cou
Slide 10: BTX 1503: acne – Phase 2 study overview
Acne BTX 1503: acne – Phase 2 study overview 12-week randomised, double-blind, vehicle controlled study to evaluate the safety and efficacy of BTX 1503 in patients with moderate to severe acne For personal use only Design Endpoints • 5 dose groups: ~360 subjects • Primary endpoints: – absolute chang
Slide 11: BTX 1503: acne – next steps
Acne BTX 1503: acne – next steps Botanix is pursuing a rapid clinical development strategy to accelerate product commercialisation and timing to first revenues For personal use only • Phase 2 clinical study started early 3Q CY2018 and will take approximately 12 months to complete • Study designed to
Slide 12: BTX 1204: atopic dermatitis – mechanism of action
Atopic BTX 1204: atopic dermatitis – mechanism of action dermatitis Atopic dermatitis (and psoriasis) are both T-cell mediated inflammatory diseases of the skin For personal use only 1. During the “acute phase”, dendritic cells cause excessive Th2 and Th17 cell activation 2. During the “chronic phas
Slide 13: BTX 1204: atopic dermatitis – Phase 1b study design
Atopic BTX 1204: atopic dermatitis – Phase 1b study design dermatitis Successful 4-week treatment period, double-blind, vehicle controlled patient study concluded in late May 2018 For personal use only Design Endpoints • ~36 subjects 18 years and older (24 active / 12 vehicle) • Primary endpoints: •
Slide 14: BTX 1204: atopic dermatitis – Phase 1b study results
Atopic BTX 1204: atopic dermatitis – Phase 1b study results dermatitis BTX 1204 was twice as effective as vehicle (with efficacy still increasing) and displayed a substantial improvement in the key signs of AD 1 For personal use only Treatment success (%)2 Key takeaways 40% Efficacy still increasing
Slide 15: BTX 1204: atopic dermatitis – Phase 2 study design
Atopic BTX 1204: atopic dermatitis – Phase 2 study design dermatitis 12 week randomised, double-blind, vehicle controlled study to evaluate the safety and efficacy of BTX 1204 in patients with moderate AD For personal use only Design Endpoints • 2 dose groups: ~200 subjects • Primary endpoint: – BTX
Slide 16: BTX 1204: atopic dermatitis – next steps
Atopic BTX 1204: atopic dermatitis – next steps dermatitis BTX 1204 complements existing products in development, allowing faster development and transition times through key For personal use only regulators (FDA and DEA) • development program leverages existing data from BTX 1503 acne studies, lowe
Slide 17: BTX 1308: psoriasis – next steps
Psoriasis BTX 1308: psoriasis – next steps Botanix has commenced a Phase 1b study to test BTX 1308 against vehicle and a marketed psoriasis drug in patients For personal use only • Novel multi-drug comparison study format in the same patient, provides high quality data on BTX 1308 efficacy • Biopsy
Slide 18: BTX 1801: antimicrobial – results summary
BTX 1801: antimicrobial – results summary BTX 1801 data demonstrates potential for a new antimicrobial to treat unmet needs in skin infections together with additional benefits seen in prior Botanix studies (e.g. reduction in inflammation) For personal use only Summary of data BTX 1801 may have the
Slide 19: Experienced team
Experienced team Global team with proven experience in dermatology and a track record of securing drug approvals For personal use only Mr Matthew Callahan Corporate +IP Founder and Board Executive Director • Developed 3 products to date that have receieved FDA approval, 1 pending approval • Ex-inves
Slide 20: Key catalysts
Key catalysts Significant clinical and operational milestones across multiple programs expected over the next 12 months For personal use only Indicative activities and milestones 3Q CY2018 4Q CY2018 1Q CY2019 2Q CY2019 First patient enrolled in Phase 2 study BTX 1503 Acne Patient enrolment complete
Slide 21: Contact us
For personal use only Contact us Matt Callahan Visit us Botanix Pharmaceuticals www.botanixpharma.com Founder and Board Executive Director Follow us on social media P: +1 215 767 4184 E: mcallahan@botanixpharma.com 20 Botanix Pharmaceuticals Limited (ASX:BOT)
Botanix Pharmaceuticals — Investor Presentation (December 2018) on 6ix